CDK9 and cancer: Similarly, the CDK2/CDK9 inhibitor CYC065 (Cyclacel) was found to induce mitotic catastrophe in CIN+ cancer cells, restraining tumour growth and underscoring its potential to treat cancers that display high-grade aneuploidy and substantial intratumoural karyotype heterogeneity [127].